The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A thermostable messenger RNA based vaccine against rabies
Open accessAbstract
Although effective rabies virus vaccines have been existing for decades, each year, rabies virus infections still cause around 50.000 fatalities worldwide.Most of these cases occur in developing countries, where these vaccines are not available.The reasons for this are the prohibitive high costs of cell culture or egg grown rabies virus vaccines and the lack of a functional cold chain in many regions in which rabies virus is endemic.Here, we describe the excellent temperature resistance of a non-replicating mRNA based rabies virus vaccine encoding the rabies virus glycoprotein (RABV-G).Prolonged storage of the vaccine from -80˚C to up to +70˚C for several months did not impact the protective capacity of the mRNA vaccine.Efficacy after storage was demonstrated by the induction of rabies specific virus neutralizing antibodies and protection in mice against lethal rabies infection.Moreover, storing the vaccine at oscillating temperatures between +4˚and +56˚C for 20 cycles in order to simulate interruptions of the cold chain during vaccine transport, did not affect the vaccine's immunogenicity and protective characteristics, indicating that maintenance of a cold chain is not essential for this vaccine. Author summaryConventional prophylactic vaccines require transport and storage under controlled temperatures in an unbroken cold chain.Therefore, distribution of many vaccines is restricted to areas where the cold chain can be maintained which excludes especially rural areas in many countries from continues vaccine supply.Unfortunately, some diseases that can be prevented by vaccination, like the rabies virus infection, are still endemic in such areas.Therefore, logistic reasons often prevent delivery of life saving vaccines to areas in which they are most needed.Here, we describe an mRNA vaccine encoding the rabies virus glycoprotein (RABV-G) that remains protective in a mouse challenge model upon storage at highly variable temperatures.These results suggest that such a vaccine allows storage outside the cold chain and can therefore reach all areas of the world where rabies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both CVnCoV and CV2CoV are based on RNActive technology4–7 and consist of non-chemically modified sequence-engineered mRNA without pseudouridine6–12.”
From Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredIn the citing paper
“A more recent storage approach involves employing freeze-drying to mRNA vaccine conservation, which was shown to effectively reduce storage requirements, being thus considered a promising technique to improve mRNA vaccine stability.472,473”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [472]
In the citing paper
“In preclinical studies, CureVac demonstrated that its sequence-optimized RABV-G vaccine against rabies could withstand exposure to temperatures ranging from −80 °C to +70 °C for several months243.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [243]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Self-citationCliquet, F., Aubert, M., & Sagné, L. (1998) · Journal of Immunological Methods · doi:10.1016/s0022-1759(97)00212-3 · Cited by 432
Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335
Freezing temperatures in the vaccine cold chain: A systematic literature review
Matthias, D. M., Robertson, J., Garrison, M. M., Newland, S., & Nelson, C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.052 · Cited by 304
Opportunities and challenges of developing thermostable vaccines
Chen, D., & Kristensen, D. D. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.20 · Cited by 227
Schnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 212
Self-citationNucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 180
Vaccination with Messenger RNA (mRNA)
Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126
Long-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115
Flagged first, then by citations
Research works printed but not linked: 1
- Montagnon B, Fanget B (1996) Purified Vero cell vaccine for humans, WHO Laboratory techniques in rabies 4th edition, chapter 26. 4.
Cited by
Sorted by citations
Items 101–117 of 117
RNA therapeutics for infectious diseases
Tu, L. M. T. P. P. L. M., Pham, T. T. D., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.002 · Cited by 1
Lyophilized vaccine development
Payton, N. M., Lodaya, R. N., & Padilla, A. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00002-7 · Cited by 1
Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1
Fu, J., Feng, S., Du, B., Dong, H., Lin, J., & Yongfeng, J. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0376 · Cited by 1
Nelwan, M. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3178506
Covid-19 and Its Vaccine Development: A Narrative Review
Septinia, R., & Hasmono, D. (2021) · Jurnal Sains dan Kesehatan · doi:10.25026/jsk.v3i6.444
Constantinescu, E. M., Chivaran, A. I., & Constantinescu, C.-A. (2022) · Jurnal Medical Brasovean · doi:10.31926/jmb.2021.1.6
Mechanism, applications and of mRNA vaccines
Wang, C. (2023) · Highlights in Science Engineering and Technology · doi:10.54097/6apbkw71
Abdelkhalek, A. F., & Daly, J. M. (2024) · Zoonotic Diseases · doi:10.3390/zoonoticdis4040021
mRNA Vaccines: Unlocking Potential, Exploring Applications, and Envisioning Future Horizons
Mishra, G., Rathee, S., Garg, M., & Patil, U. K. (2025) · Current Drug Delivery · doi:10.2174/0115672018320938241121075859 · Cited by 1
Shankar, D., Mishra, D. K., Singh, A., Pathak, N., Minocha, N., Pandey, P., & Malhotra, P. (2025) · Current Nanomedicine · doi:10.2174/0124681873339647250214070805
Rangaraj, R., & Sunkar, S. (2025) · World Academy of Sciences Journal · doi:10.3892/wasj.2025.378
Qualification of a quantitative stability indicating potency assay for mRNA-LNP vaccine candidates
Bzami, A., Estrada, M., Schofield, T., & White, J. A. (2026) · Gates Open Research · doi:10.12688/gatesopenres.16382.1
Working toward a single-dose vaccine for rabies post-exposure prophylaxis
Graf, T. P., & McHugh, K. J. (2026) · Future Virology · doi:10.1080/17460794.2026.2667092
Chowdhury, A., Silva-Santos, A. R., Azevedo, A. M., & Rathore, A. S. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04132-1
mRNA Vaccines as Novel Immunotherapeutic Approaches in Gastrointestinal Cancers
Ghidini, M., Novazzi, F., Denaro, N., Petrillo, A., Ratti, M., Salati, M., Malvaso, R., Marco, L. D., Parisi, A., & Hahne, J. C. (2026) · Cells · doi:10.3390/cells15181673
Rathore, A. S., Guillarme, D., Beck, A., Peruri, V., & Dubey, S. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119179
Metadata
- Authors
- Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., & Petsch, B.
- Affiliations
- Friedrich-Loeffler-Institut (DE)
- CureVac (Germany) (DE)
- Corresponding author
- Petsch, Benjamin
- Venue
- PLOS Neglected Tropical Diseases
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-12-07
- Volume
- 11
- Issue
- 12
- Pages
- e0006108
- ISSN
- 1935-2727 (ISSN-L)
- 1935-2735
- PMC
- PMC5737050
- OpenAlex
- W2772901255
- Cited by
- 117
- References
- 18
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 12 · 2023: 19 · 2022: 26 · 2021: 22 · 2020: 14 · 2019: 5 · 2018: 4
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Update notices
- new_version (2017-12-19)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS neglected tropical diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OpenAgrar (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bundesministerium für Bildung und Forschung (02PK2178)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › Rabies epidemiology and control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- rabies virus, mRNA vaccines, rabies virus glycoprotein, thermostable vaccine, cold chain, vaccine storage, vaccine transport, virus-neutralizing antibodies, non-replicating vaccine, rabies prevention
- MeSH terms
- Immunogenicity, Vaccine, Animals, Antibodies, Viral, Antigens, Viral, Glycoproteins, Rabies, Rabies Vaccines, Rabies virus, RNA, Messenger, Temperature, Vaccines, Synthetic, Viral Envelope Proteins, Mice, Antibodies, Neutralizing, Vaccine Potency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review